PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Conditions: Sickle Cell Disease

First Posted Date: 2019-05-09

Last Posted Date: 2023-07-18

Lead Sponsor: Pfizer

Registration Number: NCT03943615

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
The John Hopkins Hospital, Baltimore, Maryland, United States

and more 15 locations

Trial for Treatment Refractory Trigeminal Neuralgia

Phase 2

Terminated

Conditions: Trigeminal Neuralgia

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2019-05-08

Last Posted Date: 2024-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 65

Registration Number: NCT03941834

Locations: 🇺🇸
Center for Neurohealth DBA Kaizen Brain Center, La Jolla, California, United States
🇺🇸
Imaging Clinic at Stanford Neuroscience Health Center, Palo Alto, California, United States
🇺🇸
Stanford Neuroscience Health Center- SNHC Pharmacy, Palo Alto, California, United States

and more 16 locations

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Phase 3

Active, not recruiting

Conditions: Hemophilia B
Hemophilia A

Interventions: Drug: PF-06741086

First Posted Date: 2019-05-06

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 186

Registration Number: NCT03938792

Locations: 🇺🇸
Washington Institute for Coagulation, Seattle, Washington, United States
🇨🇳
Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇺🇸
USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States

and more 61 locations

A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04965842
Drug: Probenecid

First Posted Date: 2019-05-03

Last Posted Date: 2019-10-18

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03937258

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

Conditions: Migraine

First Posted Date: 2019-05-01

Last Posted Date: 2023-02-23

Lead Sponsor: Pfizer

Registration Number: NCT03934086

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 14C-PF-06651600
Drug: 14C-PF-06651600 IV
Drug: PF-06651600

First Posted Date: 2019-04-29

Last Posted Date: 2019-07-24

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT03929510

Locations: 🇳🇱
PRA Health Sciences Utrecht, Utrecht, Netherlands
🇳🇱
PRA Health Sciences, Groningen, Netherlands

Real-World Observational Study Of Zavicefta to Characterize Use Patterns

Completed

Conditions: Infection

First Posted Date: 2019-04-22

Last Posted Date: 2024-06-21

Lead Sponsor: Pfizer

Target Recruit Count: 572

Registration Number: NCT03923426

Locations: 🇦🇷
Hospital Aleman, Buenos Aires, Argentina
🇦🇷
Hospital Britanico de Buenos Aires, Caba, Argentina
🇦🇷
Hospital Italiano, Ciudad Autonoma Buenos Aires, Argentina

and more 42 locations

UK Ibrance Patient Program (IPP) Study

Completed

Conditions: HR+/HER2- Locally Advanced, Metastatic Breast Cancer

First Posted Date: 2019-04-19

Last Posted Date: 2023-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 191

Registration Number: NCT03921866

Locations: 🇬🇧
Royal Cornwall Hospital, Truro, Cornwall, United Kingdom
🇬🇧
Guys and St Thomas' NHS Trust, London, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

and more 5 locations

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

Phase 3

Completed

Conditions: Clostridium Difficile Associated Disease

Interventions: Biological: Clostridium difficile
Biological: Placebo

First Posted Date: 2019-04-17

Last Posted Date: 2024-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 1994

Registration Number: NCT03918629

Locations: 🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸
Martin Diagnostic Clinic, Tomball, Texas, United States
🇺🇸
Acevedo Clinical Research Associates, Miami, Florida, United States

and more 44 locations

Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06700841 cream
Drug: White petrolatum

First Posted Date: 2019-04-16

Last Posted Date: 2019-05-24

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT03916250

Locations: 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy